MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to US$400 million in the company, including up to US$375 million in non-dilutive capital for capped royalty payments on certain products and up to US$25 million in equity.
Latham & Watkins LLP represents MeiraGTx in the transaction with a finance team led by partner Todd Trattner, with associates Jing Cao and Will Sedgwick. Advice was also provided on corporate matters by partners Keith Halverstam and Jennifer Yoon; on healthcare regulatory matters by partners Betty Pang and Nathan Beaton, with associate Evan Miller; on tax matters by partners Eric Cho and Karl Mah, with associate Sam Duncan; on ERISA matters by partner Julie Crisp; on intellectual property matters by partner John McGaraghan, with associate Preeta Reddy; on data privacy and cybersecurity matters by partner Heather Deixler; on UK finance matters by Ross Pooley, with associates Emma Lynam, Dominic Puri, and Ohana Mei Naidu; on UK real estate matters by partners Quentin Gwyer and Calvin Ng, with associates Sam Emmett and Costa Thrasyvoulou; on US finance matters by partner Dennis Lamont; and on funds regulatory matters by Washington, D.C. counsel Meghan Carey, with associate Katherine Ryan.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
